Certara Shareholders Elect Directors, Ratify Auditor

RADNOR, PA - Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation with a market capitalization of $1.86 billion, announced the results of its annual stockholders meeting held on May 21, 2025. According to InvestingPro data, the company maintains strong financial health with a 60.26% gross margin and healthy liquidity ratios, despite experiencing challenging market conditions with a 34% decline in stock price over the past year. The meeting saw the election of Class II directors and the ratification of the company’s independent auditor for the fiscal year 2025. The company’s financial position shows resilience, with InvestingPro analysis indicating liquid assets exceeding short-term obligations and moderate debt levels.

Four Class II directors were elected to the Certara Board of Directors to serve until the 2028 annual meeting of stockholders. The elected directors are Eran Broshy, Cynthia Collins, John Reynders, and Matthew Walsh. The votes for each director were as follows: Broshy received 101,414,836 votes for and 44,496,504 withheld; Collins had 135,130,774 votes for and 10,780,566 withheld; Reynders garnered 145,466,015 votes for and 445,325 withheld; Walsh received 131,743,940 votes for and 14,167,400 withheld. All four directors also had 4,922,800 broker non-votes each.

Additionally, stockholders ratified the appointment of RSM US LLP as Certara’s independent registered public accounting firm for the 2025 fiscal year. The proposal was approved with 150,415,340 votes for, 335,712 against, and 83,088 abstentions.

Furthermore, the compensation of the company’s named executive officers for the most recently completed fiscal year was approved on a non-binding advisory basis. The proposal received 139,119,677 votes for, 6,709,969 against, and 81,694 abstentions, along with 4,922,800 broker non-votes.

The annual meeting’s proposals were described in detail in the proxy statement filed with the Securities and Exchange Commission on April 8, 2025. The company has confirmed these results in an 8-K filing with the SEC.

Certara specializes in services related to prepackaged software, providing technology solutions that support the drug development process. The company’s headquarters are located at 4 Radnor Corporate Center, Suite 350, Radnor, PA 19087.

This news report is based on information contained in a recent SEC filing by Certara, Inc.

In other recent news, Certara Inc . reported strong financial results for the first quarter of 2025, surpassing analyst expectations. The company achieved an earnings per share (EPS) of $0.14, exceeding the forecasted $0.11, and reported a total revenue of $106 million, which marks a 10% increase year-over-year. This robust performance was highlighted by a 20% year-over-year increase in adjusted EBITDA, reaching $34.8 million. Barclays (LON:BARC) analyst Luke Sergott upgraded Certara’s stock rating from Equal Weight to Overweight and raised the price target to $14, citing the company’s strategic positioning and effective execution amidst industry challenges. Meanwhile, JMP Securities maintained its Market Perform rating for Certara, following the company’s first-quarter earnings report. Certara’s recent developments also include a $100 million share repurchase program and continued expansion of its AI capabilities and biosimulation offerings. The FDA’s recent announcement about phasing out animal testing has positively impacted Certara, with the company’s non-animal navigator offering receiving early positive responses. These developments position Certara to potentially accelerate its business performance in the latter half of the year and into 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.